Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.
about
Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agentsHepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients.Iron dosing in kidney disease: inconsistency of evidence and clinical practice.Comment on: Evaluation of erythrocyte and reticulocyte parameters as indicative of iron deficiency in patients with anemia of chronic disease.Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD TrialSerum levels of the hepcidin-20 isoform in a large general population: the Val Borbera study.Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease.Iron deficiency or anemia of inflammation? : Differential diagnosis and mechanisms of anemia of inflammationThe iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist.Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?Hepcidin quantification: methods and utility in diagnosis.Markers of iron status in chronic kidney disease.Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients.Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA.Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry.Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?Serum copper and ferroportin in monocytes of hemodialysis patients are both decreased but unassociated.Uses and interpretation of iron studies in patients on chronic dialysis.Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin.Determination of functional iron deficiency status in haemodialysis patients in central South Africa.Guideline for the laboratory diagnosis of functional iron deficiency.C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients.Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney DiseaseHepcidin as a potential predictor for preoperative anemia treatment with intravenous iron-A retrospective pilot studyOral Iron for Patients Receiving Dialysis: What is the Evidence?
P2860
Q28727076-255F7C1F-46D6-4A72-9D27-EA33E5223393Q35003742-AD8D75F8-6947-46A6-A5B7-9EAEC083B659Q35022235-4F8DEDEC-9137-4AFF-9162-1DD69F31BCF1Q35244441-B371A669-B2B3-432D-9358-719FA911211BQ35957777-0CBFCEB8-80B9-4E0A-B154-7323615FD221Q36045015-45F3F1FF-A4F8-4396-A249-99D1D9D21472Q36431697-9A8FF14C-8630-4247-A7BA-2265D4B26F88Q36471843-FB5F250A-20E6-4B5F-B30B-49186EB48419Q37341829-9F40B98F-D0F9-4B8B-A8C3-1DC7AD5FC833Q37542851-02282B78-1711-4535-B92C-4484C9490614Q37852626-6397FD8A-9F29-4C13-A816-AA2338622CB1Q38051056-112BB24C-D5FD-4160-9F5C-97AD88D9DFCBQ38215856-EF88FBF2-0825-4CA5-B41E-E3F6A05307A2Q38887263-38A10DD6-D73F-4BEE-B123-6D4C65D5935FQ39278083-51D86C24-9EFE-4E3E-B961-86DB05326995Q39582910-39E27899-FA2E-4DAA-AF0E-8413D80CBC33Q40813065-15E7622F-3D71-42D7-8F1E-6C59A22CDF66Q42276525-B5F87AE1-262C-4E87-B411-D9C475BD2461Q42705739-AC55FED0-20FC-4EE0-9CEA-8964C0772E52Q46213470-45ECD335-2D4B-4887-ADEE-66BFA8BDA00FQ47994810-5E0C0A2C-C716-4695-A77D-7C1F13DCDE36Q50241965-B52E28B3-0E98-47AD-A502-E9A131539A39Q51076582-6921D8D4-4E95-49CF-AE42-9E63DE1E3725Q53810360-8E376A88-FB7D-46E0-99C6-6EDABDE36162Q58700150-A100509A-0B86-42A4-8253-94E595EE035FQ58796278-99FA1BB8-22EF-4DAE-B7C2-B2B479AD8D00Q59167466-92C66C31-4376-4569-8619-921F85C66586
P2860
Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Hepcidin is not useful as a bi ...... hropoiesis-stimulating agents.
@ast
Hepcidin is not useful as a bi ...... hropoiesis-stimulating agents.
@en
type
label
Hepcidin is not useful as a bi ...... hropoiesis-stimulating agents.
@ast
Hepcidin is not useful as a bi ...... hropoiesis-stimulating agents.
@en
prefLabel
Hepcidin is not useful as a bi ...... hropoiesis-stimulating agents.
@ast
Hepcidin is not useful as a bi ...... hropoiesis-stimulating agents.
@en
P2093
P356
P1476
Hepcidin is not useful as a bi ...... hropoiesis-stimulating agents.
@en
P2093
Albino Poli
Annalisa Castagna
Antonio Lupo
Domenico Girelli
Giovanna De Matteis
Giovanni Pietro Solero
Natascia Campostrini
Nicola Tessitore
Valeria Bedogna
William Mantovani
P304
P356
10.1093/NDT/GFQ321
P407
P577
2010-06-10T00:00:00Z